Procalcitonin as a biomarker for infection-related mortality in cancer patients

Sedef, Ali Murat; Kose, Fatih; Mertsoylu, Hüseyin; Ozyilkan, Ozgür

doi:10.1097/spc.0000000000000142

Cited by 10 publications

(8 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Procalcitonin is an important peptide hormone involved in many types of diseases, especially in those with infection-related diseases [25][26][27][28][29]. The level of procalcitonin rises in a response to a proinflammatory stimulus, especially of bacterial origin.…”

Section: Discussionmentioning

confidence: 99%

Serum Procalcitonin Level and Mortality Risk in Critically ill Patients with Ventilator-Associated Pneumonia

Li¹,

Zhao

Li³

2015

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: The prognostic role of serum procalcitonin level in critically ill patients with ventilator-associated pneumonia was unclear. The aim of our study was to investigate the relationship between serum procalcitonin level and mortality risk in critically ill patients with ventilator-associated pneumonia. Methods: Data of critically ill patients with ventilator-associated pneumonia were retrospectively collected. Demographics, comorbidities, and serum procalcitonin level were extracted from electronic medical records. The primary outcome was mortality within two months after diagnosis. Multivariable Cox regression analyses were performed to assess the prognostic role of serum procalcitonin level in those patients. Results: A total of 115 critically ill patients with ventilator-associated pneumonia were enrolled in our study. Serum procalcitonin level was not associated with age, gender, or other comorbidities. Univariate Cox regression model showed that high serum procalcitonin level was associated increased risk of morality within 2 months after diagnosis (OR = 2.32, 95% CI 1.25-4.31, P = 0.008). Multivariable Cox regression model showed that high serum procalcitonin level was independently associated increased risk of morality within 2 months after diagnosis (OR = 2.38, 95% CI 1.26-4.50, P = 0.008). Conclusion: High serum procalcitonin level is an independent prognostic biomarker of mortality risk in critically ill patients with ventilator-associated pneumonia, and it's a promising biomarker of prognosis in critically ill patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum Procalcitonin Level and Mortality Risk in Critically ill Patients with Ventilator-Associated Pneumonia

Li¹,

Zhao

Li³

2015

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…Procalcitonin has been suggested to be used in early diagnosis and exclusion of infection in cancer patients in literature. 21 However, basal procalcitonin levels have been reported to be associated with total and cancer mortality in a prospective cohort study that was in the secondary analysis qualification and included 3322 patients. 22 Based on those findings, it has been proposed that procalcitonin can exacerbate procarcinogenic inflammatory response, impair anti-tumor immune mechanisms, and act as disease mediator in cancer.…”

Section: Discussionmentioning

confidence: 99%

Comparison of diagnostic and prognostic utility of lactate and procalcitonin for sepsis in adult cancer patients presenting to emergency department with systemic inflammatory response syndrome

Keçe

Yaka

Yılmaz

et al. 2016

Turkish Journal of Emergency Medicine

View full text Add to dashboard Cite

ObjectivesDifferentiating sepsis from other noninfectious causes of systemic inflammatory response syndrome (SIRS) in cancer patients is often challenging. Although lactate and procalcitonin have been studied extensively regarding sepsis management, little is known about their utility in cancer patients.This study aimed to compare the diagnostic and prognostic utility of lactate and procalcitonin for sepsis in cancer patients.Material and methodsThis prospective case-control study was conducted with adult cancer patients presenting to emergency department (ED) with at least two SIRS criteria. The infection status of each patient was determined retrospectively.Main diagnostic variables were calculated for diagnostic and prognostic utilities of lactate and procalcitonin.ResultsAmong 86 patients, mean age was 61. Twenty-two (25.6%) were determined in the sepsis group.In the ROC analysis, a lactate value of 1 mmol/L predicted sepsis with 86.36% (95%CI: 65.1%–97.1%) sensitivity and 28.12% (95%CI: 17.6%–40.76%) specificity. A procalcitonin value of 0.8 ng/mL yielded a sensitivity of 63.64% (95%CI: 40.7%–82.8%) and 76.56% (95%CI: 63.4%–86.2%) specificity for differential diagnosis of sepsis in cancer patients.Lactate and procalcitonin showed similar abilities in differentiating sepsis from non-infective SIRS in cancer patients [AUROCs of 0.638 (95%CI:0.527–0.739) vs 0.637 (95%CI:0.527–0.738), respectively. p = 0.994].They were also similar in predicting poor clinical outcome with AUROCs of 0.629 (95%CI:0.518–0.731) and 0.584 (95%CI: 0.473–0.69), respectively (p = 0.577).ConclusionsThe results of this study indicated that, none of the lactate and procalcitonin can be recommended alone to differentiate sepsis from non-infectious SIRS and to predict the poor clinical outcomes in adult cancer patients with SIRS in the ED.

show abstract

“…Evaluation of procalcitonin in the setting of allogeneic HSCT is limited, with no data regarding its role in the setting of ES. A clinical utility of using procalcitonin in oncology in general is demonstrated …”

Section: Introductionmentioning

confidence: 99%

“…A clinical utility of using procalcitonin in oncology in general is demonstrated. [14][15][16][17] On the basis of the potential clinical utility in being able to accurately diagnose ES and given the limited analysis of biomarkers for ES, particularly in children, we sought to systematically and prospectively Information was stored in a secure database.…”

Section: Introductionmentioning

confidence: 99%

Procalcitonin and cytokine profiles in engraftment syndrome in pediatric stem cell transplantation

Shah

Watson

Yates

et al. 2016

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

Procalcitonin as a biomarker for infection-related mortality in cancer patients

Abstract: In this article, we focus on procalcitonin and its potential role in differentiating cancer and infection-induced inflammation. Using this strategy may significantly reduce the usage of empirical broad-spectrum antibiotics and result in earlier discharge of patients.

Cited by 10 publications

References 41 publications

Serum Procalcitonin Level and Mortality Risk in Critically ill Patients with Ventilator-Associated Pneumonia

Serum Procalcitonin Level and Mortality Risk in Critically ill Patients with Ventilator-Associated Pneumonia

Comparison of diagnostic and prognostic utility of lactate and procalcitonin for sepsis in adult cancer patients presenting to emergency department with systemic inflammatory response syndrome

Procalcitonin and cytokine profiles in engraftment syndrome in pediatric stem cell transplantation

Contact Info

Product

Resources

About